Recruiting
Phase 2

BI 1815368

Sponsor:

Boehringer Ingelheim

Code:

NCT06962839

Conditions

Macular Edema

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BI 1815368

Placebo

Study Details

Brief summary:

This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take part. The purpose of this study is to find out whether a medicine called BI 1815368 improves sight in people with CI-DME and to find the most suitable dose.

This study has 2 parts. In the first part, participants are put into 2 groups of equal size randomly, which means by chance. One group takes BI 1815368 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1815368 tablets but do not contain any medicine. In the second part, participants are put into 4 groups of equal size randomly. 3 groups take different daily doses of the study medicine, BI 1815368, while 1 group takes placebo. All participants take tablets twice a day for about 11 months.

Participants are in the study for about 1 year. During this time, they visit the study site 16 times. At visits, doctors check the participant's vision and collect information on any health problems. They take detailed pictures of the eye. The changes over time are compared between the groups to see if the treatment works.

Conditions

Macular Edema

Study ID

NCT06962839

Start date

Jun 5, 2025

Status verified date

Sep, 2026

Completion date

Sep 29, 2027

Anticipated

Primary completion date

Sep 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion criteria:

  • ≥18 years of age
  • Diagnosis of diabetes mellitus (DM) (type 1 or type 2), Haemoglobin A1C (HbA1c) <12% treated with stable medication for at least 30 days prior to Day 1; no already-set plans for major changes in DM medication (e.g. start of new medication) at the time of screening and baseline
  • Centre-involved diabetic macular edema (CI-DME) confirmed on spectral domain optical coherence tomography (SD-OCT) with central subfield foveal thickness (CST) ≥320 µm in the study eye at screening
  • Best corrected visual acuity (BCVA) visual acuity Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye between 24 and 78 (Snellen equivalent range 20/320 to 20/32) at screening Further inclusion criteria apply.

Exclusion criteria:

  • Macular edema considered to be due to other causes than CI-DME in the study eye
  • Proliferative diabetic retinopathy or iris neovascularisation (including the anterior chamber angle) in the study eye
  • Any intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment within 4 months before Day 1 (other than faricimab or aflibercept 8mg), and within 6 months before Day 1 for faricimab or aflibercept 8 mg, and/or more than 4 prior IVT injections with anti-VEGF treatment in total in the study eye
  • Any history of panretinal photocoagulation, macular laser photocoagulation, vitreoretinal surgery, IVT or periocular corticosteroid treatment (within 12 months before Day 1), history of fluocinolone ophthalmic implant or dexamethasone IVT implant before Day 1, or topical steroid or NSAID treatment (within 30 days before Day 1)
  • Active ocular inflammation of any history of intraocular inflammation within 1 year
  • Aphakia or total absence of the posterior capsule; Yttrium aluminium garnet (YAG) laser capsulotomy in the study eye is permitted if more than 2 months prior to Day 1 Further exclusion criteria apply.

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Cohort 1: Treatment arm

placebo comparator: Cohort 1: Placebo arm

placebo comparator: Cohort 2: Placebo arm

experimental: Cohort 2: Treatment arm, low dose

experimental: Cohort 2: Treatment arm, medium dose

experimental: Cohort 2: Treatment arm, high dose

Interventions

BI 1815368

BI 1815368

Placebo

Placebo matching BI 1815368

Primary outcome measure

  • Occurrence (yes/no) of a gain of ≥10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters compared with baseline in the study eye at Week 48 [ Time Frame: at baseline, at week 48 ]

Central Contacts and Locations

Central contacts

Locations

Win Retina

Recruiting

Arcadia, California, United States, 91006

Contacts

Retina Associates of Southern California

Recruiting

Huntington Beach, California, United States, 92647

Contacts

Retinal Consultants Medical Group, Inc

Recruiting

Modesto, California, United States, 95356

Contacts

Doheny Eye Center UCLA Arcadia

Recruiting

Pasadena, California, United States, 91103

Contacts

Retina Consultants of San Diego

Recruiting

Poway, California, United States, 92064

Contacts

West Coast Retina Medical Group, Inc.

Recruiting

San Francisco, California, United States, 94109

Contacts

Colorado Retina Associates

Recruiting

Lakewood, Colorado, United States, 80228

Contacts

Advanced Research Institute

Recruiting

Pompano Beach, Florida, United States, 33064

Contacts

Center for Retina and Macular Disease

Recruiting

Winter Haven, Florida, United States, 33880

Contacts

Associated Vitreoretinal and Uveitis Consultants

Recruiting

Carmel, Indiana, United States, 46032

Contacts

University of Kansas Medical Center

Recruiting

Kansas City, Kansas, United States, 66160

Contacts

Cumberland Valley Retina Consultants

Recruiting

Hagerstown, Maryland, United States, 21740

Contacts

Sierra Eye Associates

Recruiting

Reno, Nevada, United States, 89502

Contacts

North Carolina Retina Associates

Recruiting

Wake Forest, North Carolina, United States, 27587

Contacts

Verum Research, LLC

Recruiting

Eugene, Oregon, United States, 97401

Contacts

Tennessee Retina

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

Austin Research Center for Retina, PLLC

Recruiting

Austin, Texas, United States, 78705

Contacts

Austin Retina Associates

Recruiting

Austin, Texas, United States, 78705

Contacts

Austin Clinical Research, LLC

Recruiting

Austin, Texas, United States, 78750

Contacts

Texas Retina Associates

Recruiting

Dallas, Texas, United States, 75231

Contacts

Retina Center Of Texas

Recruiting

Southlake, Texas, United States, 76092

Contacts

Retina Consultants of Texas

Recruiting

The Woodlands, Texas, United States, 77384

Contacts

More Information

Sponsor

Boehringer Ingelheim

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-09-03.